Cargando…

Influence of CYP2C19 genetic variants and smoking on dual antiplatelet efficacy in patients with coronary artery disease

INTRODUCTION: This study aimed to investigate the effects of smoking and CYP2C19 gene polymorphism on antiplatelet therapy to specify the most optimized and accurate antiplatelet therapy for different populations. METHODS: This study included 6,353 patients with coronary artery disease (CAD). In tot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Yujing, Sun, Yan, Zhang, Dai, Ma, Xiaoteng, Liu, Chi, Hu, Chengping, Sun, Tienan, Zhao, Ziwei, Liu, Xiaoli, Zhou, Yujie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902702/ https://www.ncbi.nlm.nih.gov/pubmed/36760562 http://dx.doi.org/10.3389/fcvm.2023.1105001

Ejemplares similares

A Novel Risk Scoring Tool to Predict Saphenous Vein Graft Occlusion After Cardiac Artery Bypass Graft Surgery
por: Cheng, Yujing, et al.
Publicado: (2021)

CYP2C19 genotype and platelet aggregation test-guided dual antiplatelet therapy after off-pump coronary artery bypass grafting: A retrospective cohort study
por: Yao, Haoyi, et al.
Publicado: (2022)

Prognostic implication of serum glycated albumin for patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention
por: Liu, Chi, et al.
Publicado: (2022)

A Synergistic Effect of Lp(a) and GRACE Score on Cardiovascular Risk in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Cohort Study From China
por: Hu, Chengping, et al.
Publicado: (2021)

Predictive worth of estimated glucose disposal rate: evaluation in patients with non-ST-segment elevation acute coronary syndrome and non-diabetic patients after percutaneous coronary intervention
por: Liu, Chi, et al.
Publicado: (2022)

Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review
por: Elliott, Jesse, et al.
Publicado: (2017)

Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry
por: Christ, Günter, et al.
Publicado: (2014)

Dual antiplatelet therapy following percutaneous coronary intervention: protocol for a systematic review
por: Elliott, Jesse, et al.
Publicado: (2019)

Correlation between estimated glucose disposal rate and in-stent restenosis following percutaneous coronary intervention in individuals with non-ST-segment elevation acute coronary syndrome
por: Liu, Chi, et al.
Publicado: (2022)

Incorporation of Laboratory Test Biomarkers Into Dual Antiplatelet Therapy Score Improves Prediction of Ischemic and Bleeding Events in Post-percutaneous Coronary Intervention Patients
por: Sun, Chengming, et al.
Publicado: (2022)

Short dual antiplatelet therapy and dual antiplatelet therapy de-escalation after primary percutaneous intervention: For whom and how
por: Muthspiel, Marie, et al.
Publicado: (2022)

Dual Antiplatelet Therapy in Coronary Artery Disease
por: Sharma, Raghav, et al.
Publicado: (2020)

Editorial: The individualization of antiplatelet therapy in coronary artery disease: escalation or de-escalations
por: Lee, Sang Yeub, et al.
Publicado: (2023)

Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease
por: Tung, Ying-Chang, et al.
Publicado: (2020)

Reduction or de-escalation of dual antiplatelet therapy intensity or duration in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A mini-review
por: Farag, Mohamed, et al.
Publicado: (2022)

Causal Relationship of Coronary Artery Calcium on Myocardial Infarction and Preventive Effect of Antiplatelet Therapy
por: Limpijankit, Thosaphol, et al.
Publicado: (2022)

Dual Loading Antiplatelet Therapy in Patients With Acute Coronary Syndrome and High Bleeding Risk Undergoing Percutaneous Coronary Intervention: Findings From the Improving Care for Cardiovascular Disease in China Project
por: Yan, Yan, et al.
Publicado: (2022)

Duration of Dual Antiplatelet Therapy After Implantation of Drug-Coated Balloon
por: Zhang, Yuxuan, et al.
Publicado: (2021)

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy
por: Nguyen, Anh B., et al.
Publicado: (2022)

Dual Antiplatelet Therapy vs. Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis
por: Zhang, Yipeng, et al.
Publicado: (2021)

Antiplatelet therapy in patients with myocardial infarction with non-obstructive coronary arteries: A clinical perspective
por: Chen, Wenjie, et al.
Publicado: (2023)

Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain)
por: Ribera, Aida, et al.
Publicado: (2019)

Duration and clinical outcomes of dual antiplatelet therapy following percutaneous coronary intervention for acute coronary syndrome: A multicentre “real-world practice” registry-based study
por: Vergara-Uzcategui, Carlos E., et al.
Publicado: (2023)

Study protocol for a randomised controlled trial: harmonising optimal strategy for treatment of coronary artery stenosis — coronary intervention with next-generation drug-eluting stent platforms and abbreviated dual antiplatelet therapy (HOST-IDEA) trial
por: Kim, Chi-Hoon, et al.
Publicado: (2017)

Very late bioresorbable scaffold thrombosis after discontinuation of dual antiplatelet therapy
por: Karanasos, Antonios, et al.
Publicado: (2014)

Duration of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With New Generation Stents: A Meta-Analysis of Randomized Controlled Trials
por: Zhang, Wen-Jiao, et al.
Publicado: (2021)

Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
por: Huang, Sheng-Wei, et al.
Publicado: (2022)

Benefit and Risk of Prolonged Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Elevated Lipoprotein(a) Concentrations
por: Cui, Kongyong, et al.
Publicado: (2021)

Is the duration of dual antiplatelet therapy (DAPT) excessive in post-angioplasty in chronic coronary syndrome? Data from the France-PCI registry (2014–2019)
por: Mezier, A., et al.
Publicado: (2023)

Effect of dual antiplatelet therapy prolongation in acute coronary syndrome patients with both high ischemic and bleeding risk: insight from the OPT-CAD study
por: Na, Kun, et al.
Publicado: (2023)

Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome
por: Ma, Xiaoteng, et al.
Publicado: (2020)

Prognostic value of systemic inflammatory response index in patients with acute coronary syndrome undergoing percutaneous coronary intervention
por: Han, Kangning, et al.
Publicado: (2022)

Dual antiplatelet treatment after coronary artery bypass surgery
por: Lopez Menendez, Jose, et al.
Publicado: (2015)

Dual antiplatelet therapy for secondary prevention of coronary artery disease
por: Degrauwe, Sophie, et al.
Publicado: (2017)

Optimal duration of dual antiplatelet therapy for coronary artery disease
por: Kikkert, W. J., et al.
Publicado: (2018)

De-escalation of antiplatelet therapy in acute coronary syndromes: Why, how and when?
por: Galli, Mattia, et al.
Publicado: (2022)

Clinical Impact of Single and Dual Antiplatelet Therapy Beyond 12 Months on Ischemic Risk in Patients With Acute Myocardial Infarction
por: Roh, Ji Woong, et al.
Publicado: (2021)

Different Antiplatelet Strategies for Radial Artery Protection After Transradial Coronary Angiography—A Prospective Observational Cohort Study
por: Qin, Zheng, et al.
Publicado: (2022)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
por: Shi, Xiujin, et al.
Publicado: (2021)

Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
por: Kang, Min Gyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v8linka4um5sule9gqi20e1kh8